Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Prochlorperazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 9/20 | 0.82 |
| ▸ | LMNA | P02545 | 8/20 | 1.00 |
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 6/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | GMNN | O75496 | 3/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 3/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.82 |
| ▸ | ADRA2A | P08913 | 7/20 | 0.82 |
| ▸ | ADRA2C | P18825 | 7/20 | 0.82 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.82 |
| ▸ | HTR2A | P28223 | 7/20 | 0.82 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.82 |
| ▸ | HRH1 | P35367 | 7/20 | 0.82 |
| ▸ | DRD3 | P35462 | 7/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Prochlorperazine SCHEMBL8911628 | 1.00 | LMNA (1.00) | LMNAMAPTMAPK1SMN1; SMN2NPSR1 | |
| Prochlorperazine SCHEMBL29686418 | 1.00 | LMNA (1.00) | LMNAMAPTMAPK1SMN1; SMN2NPSR1 | |
| Prochlorperazine SCHEMBL8914157 | 1.00 | LMNA (1.00) | LMNAMAPTMAPK1SMN1; SMN2NPSR1 | |
| Prochlorperazine SCHEMBL29634451 | 1.00 | LMNA (1.00) | LMNAMAPTMAPK1SMN1; SMN2NPSR1 | |
| Prochlorperazine SCHEMBL5494383 | 1.00 | LMNA (1.00) | LMNAMAPTMAPK1SMN1; SMN2NPSR1 | |
| Prochlorperazine SCHEMBL40755 | 1.00 | LMNA (1.00) | LMNAMAPTMAPK1SMN1; SMN2NPSR1 | |
| Prochlorperazine SCHEMBL1806022 | 1.00 | LMNA (1.00) | LMNAMAPTMAPK1SMN1; SMN2NPSR1 | |
| Prochlorperazine SCHEMBL40756 | 1.00 | LMNA (1.00) | LMNAMAPTMAPK1SMN1; SMN2NPSR1 | |
| Prochlorperazine SCHEMBL28763049 | 0.95 | LMNA (0.91) | LMNAMAPTMAPK1SMN1; SMN2NPSR1 | |
| Perphenazine SCHEMBL871706 | 0.92 | MAPT (0.85) | LMNAMAPTMAPK1SMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 214 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024028324-A1 | MOLECULES FOR THE PREVENTION AND TREATMENT OF NEUROMUSCULAR DISORDERS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2024-02-08 | — | — | WO | claimed |
| WO-2018039159-A1 | MUSCARINIC M2-ANTAGONIST COMBINATION | CHASE PHARMACEUTICALS CORPORATION (US) | 2018-03-01 | — | — | WO | claimed |
| WO-2017147104-A1 | MUSCARINIC M2-ANTAGONIST COMBINATIONS | CHASE PHARMACEUTICALS CORPORATION (US) | 2017-08-31 | — | — | WO | claimed |
| US-20110224141-A1 | METHODS AND RELATED COMPOSITIONS FOR THE TREATMENT OF CANCER | STC.UNM (US) | 2011-09-15 | — | — | US | claimed |
| WO-2009148623-A2 | METHODS AND RELATED COMPOSITIONS FOR THE TREATMENT OF CANCER | STC.UNM (US) | 2009-12-10 | — | — | WO | claimed |
| CN-122094715-A | Peptide nanosponges for drug delivery | — | 2026-05-26 | — | — | CN | disclosed |
| US-20250340671-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR REDUCING THE NEUROMODULATORY EFFECT OF COCAINE | UNIVERSITY OF CINCINNATI (US) | 2025-11-06 | — | — | US | disclosed |
| US-20240197728-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING REFRACTORY EPILEPSY | INST NAT SANTE RECH MED (FR) | 2024-06-20 | — | — | US | disclosed |
| EP-4322952-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING REFRACTORY EPILEPSY | Inserm (Institut National de la Santé et de la Recherche Scientifique) (FR) | 2024-02-21 | — | — | EP | disclosed |
| WO-2024028324-A1 | MOLECULES FOR THE PREVENTION AND TREATMENT OF NEUROMUSCULAR DISORDERS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2024-02-08 | — | — | WO | disclosed |
| WO-2023235500-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR REDUCING THE NEUROMODULATORY EFFECT OF COCAINE | UNIVERSITY OF CINCINNATI (US) | 2023-12-07 | — | — | WO | disclosed |
| US-11759445-B2 | Use of Rivastigmine in preparation of anti-radiation medicament | SOOCHOW UNIVERSITY (CN) | 2023-09-19 | — | — | US | disclosed |
| US-5654281-A | Inhibiting the development of tolerance to and/or dependence on an addictive substance | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1997-08-05 | — | — | US | disclosed |
| EP-0778770-A1 | COMPOSITION ALLEVIATING PAIN, CONTAINING A NON-NARCOTIC ANALGESIC AND AN ANALGESIA ENHANCER | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1997-06-18 | — | — | EP | disclosed |
| US-5556838-A | BLOCKING N-METHYLASPARTATE RECEPTORS TO PREVENT ADDICTION | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1996-09-17 | — | — | US | disclosed |
| US-5502058-A | Method for the treatment of pain | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1996-03-26 | — | — | US | disclosed |
| WO-1996007412-A1 | COMPOSITION ALLEVIATING PAIN, CONTAINING A NON-NARCOTIC ANALGESIC AND AN ANALGESIA ENHANCER | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1996-03-14 | — | — | WO | disclosed |
| EP-0615749-A2 | Use of NMDA antagonists for the treatment of pain | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1994-09-21 | — | — | EP | disclosed |
| EP-0608893-A1 | Inhibiting the development of tolerance to and/or dependence on an additive substance | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1994-08-03 | — | — | EP | disclosed |
| US-5321012-A | Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance | VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL COLLEGE (US) | 1994-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240197728-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING REFRACTORY EPILEPSY | SLC6A13, SLC6A1, CLCN2 | DRD2 1213/4885LMNA 3265/4885MAPT 1619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.